NO20092226L - Substituerte pyrazol og triazolforbindelser som KSP-inhibitorer - Google Patents

Substituerte pyrazol og triazolforbindelser som KSP-inhibitorer

Info

Publication number
NO20092226L
NO20092226L NO20092226A NO20092226A NO20092226L NO 20092226 L NO20092226 L NO 20092226L NO 20092226 A NO20092226 A NO 20092226A NO 20092226 A NO20092226 A NO 20092226A NO 20092226 L NO20092226 L NO 20092226L
Authority
NO
Norway
Prior art keywords
triazole compounds
substituted pyrazole
ksp inhibitors
pharmaceutically acceptable
ksp
Prior art date
Application number
NO20092226A
Other languages
English (en)
Norwegian (no)
Inventor
Paul A Renhowe
Yi Xia
Kris Mendenhall
Paul A Barsanti
Annette O Walter
David Duhl
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20092226L publication Critical patent/NO20092226L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20092226A 2006-11-13 2009-06-09 Substituerte pyrazol og triazolforbindelser som KSP-inhibitorer NO20092226L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85896406P 2006-11-13 2006-11-13
PCT/US2007/084154 WO2008063912A1 (en) 2006-11-13 2007-11-08 Substituted pyrazole and triazole compounds as ksp inhibitors

Publications (1)

Publication Number Publication Date
NO20092226L true NO20092226L (no) 2009-08-12

Family

ID=39144618

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092226A NO20092226L (no) 2006-11-13 2009-06-09 Substituerte pyrazol og triazolforbindelser som KSP-inhibitorer

Country Status (32)

Country Link
US (2) US8129358B2 (ko)
EP (1) EP2091926B1 (ko)
JP (1) JP5264755B2 (ko)
KR (1) KR20090081020A (ko)
CN (1) CN101558049B (ko)
AR (1) AR063805A1 (ko)
AU (1) AU2007323998B2 (ko)
BR (1) BRPI0719002A2 (ko)
CA (1) CA2668661A1 (ko)
CL (1) CL2007003272A1 (ko)
CO (1) CO6382171A2 (ko)
CR (1) CR10787A (ko)
DO (1) DOP2009000106A (ko)
EA (1) EA017748B1 (ko)
EC (1) ECSP099326A (ko)
ES (1) ES2557478T3 (ko)
GE (1) GEP20125389B (ko)
GT (1) GT200900122A (ko)
HN (1) HN2009000968A (ko)
IL (1) IL198471A0 (ko)
MA (1) MA30959B1 (ko)
MX (1) MX2009005071A (ko)
NI (1) NI200900084A (ko)
NO (1) NO20092226L (ko)
NZ (1) NZ576640A (ko)
PE (1) PE20081169A1 (ko)
SM (1) SMP200900045B (ko)
TN (1) TN2009000178A1 (ko)
TW (1) TW200831480A (ko)
UA (1) UA97256C2 (ko)
WO (1) WO2008063912A1 (ko)
ZA (1) ZA200902940B (ko)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8129358B2 (en) * 2006-11-13 2012-03-06 Novartis Ag Substituted pyrazole and triazole compounds as KSP inhibitors
NZ577727A (en) * 2007-01-05 2012-03-30 Novartis Ag Imidazole derivatives as kinesin spindle protein inhibitors (eg-5)
EA201201404A1 (ru) 2010-04-15 2013-04-30 Новартис Аг Триазолы как ингибиторы кбв (кинезин-белок веретена)
CN103153970A (zh) * 2010-04-15 2013-06-12 诺瓦提斯公司 作为ksp抑制剂的*唑和噻唑化合物
EP2928472B1 (en) * 2012-12-05 2018-05-02 Merck Sharp & Dohme Corp. Process for making reverse transcriptase inhibitors
JP2016516035A (ja) * 2013-03-15 2016-06-02 ノバルティス アーゲー 細胞増殖阻害剤およびそれらのコンジュゲート
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
ES2759976T3 (es) 2013-12-04 2020-05-12 Merck Sharp & Dohme Proceso para fabricar inhibidores de la transcriptasa inversa
US10786578B2 (en) 2014-08-05 2020-09-29 Novartis Ag CKIT antibody drug conjugates
EP3386973B1 (en) * 2015-12-11 2020-08-12 Syngenta Participations AG Pesticidally active 1,2,4-triazole derivatives
EP4085056A1 (en) 2020-01-03 2022-11-09 Berg LLC Polycyclic amides as ube2k modulators for treating cancer

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5011472A (en) * 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5185450A (en) * 1991-02-19 1993-02-09 University Of South Florida Tetrazolium compounds for cell viability assays
AUPP042397A0 (en) * 1997-11-18 1997-12-11 Fujisawa Pharmaceutical Co., Ltd. 5-arylpyrazole compounds
JP2002541146A (ja) 1999-04-02 2002-12-03 ニューロゲン コーポレイション アリールおよびヘテロアリール融合のアミノアルキル−イミダゾール誘導体および糖尿病薬としてのその使用
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
IL149164A0 (en) 1999-10-27 2002-11-10 Cytokinetics Inc Methods and compositions utilizing quinazolinones
WO2002028839A1 (en) 2000-10-06 2002-04-11 Neurogen Corporation Benzimidazole and indole derivatives as crf receptor modulators
US20040132830A1 (en) 2001-01-19 2004-07-08 Finer Jeffrey T Triphenylmethane kinesin inhibitors
US6992082B2 (en) 2001-01-19 2006-01-31 Cytokinetics, Inc. Phenothiazine kinesin inhibitors
CA2465491A1 (en) 2001-11-07 2003-05-15 Merck & Co., Inc. Mitotic kinesin inhibitors
CA2466033A1 (en) 2001-11-08 2003-05-15 The University Of Chicago Method of treating disorder related to high cholesterol concentration
WO2003043995A1 (en) 2001-11-20 2003-05-30 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
ATE447577T1 (de) 2001-12-06 2009-11-15 Merck & Co Inc Mitotische kinesin-hemmer
DE60232994D1 (de) 2001-12-06 2009-08-27 Merck & Co Inc Inhibitoren von mitotischem kinesin
ATE424388T1 (de) 2001-12-06 2009-03-15 Merck & Co Inc Mitotische kinesinhemmer
WO2003050064A2 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2003050122A2 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
EP1461027A4 (en) * 2001-12-07 2005-09-07 Univ Virginia Commonwealth TREATMENT OF NEOPLASIA
EP1465888A2 (en) 2002-01-10 2004-10-13 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues
WO2003105855A1 (en) 2002-01-11 2003-12-24 Merck & Co., Inc. Mitotic kinesin inhibitors
US7009049B2 (en) 2002-02-15 2006-03-07 Cytokinetics, Inc. Syntheses of quinazolinones
WO2003079973A2 (en) 2002-03-08 2003-10-02 Merck & Co., Inc. Mitotic kinesin inhibitors
RU2004135554A (ru) 2002-05-09 2006-01-20 Цитокинетикс, Инк. (Us) Пиримидиноны, композиции на их основе и способы их использования
JP2005530785A (ja) 2002-05-09 2005-10-13 サイトキネティクス・インコーポレーテッド 化合物、組成物、及び方法
WO2004026226A2 (en) 2002-05-10 2004-04-01 Cytokinetics, Inc. Compounds, compositions and methods
EP1509507A4 (en) 2002-05-23 2006-09-13 Merck & Co Inc INHIBITORS OF MITOTIC KINESIN
AU2003265242A1 (en) 2002-05-23 2003-12-22 Cytokinetics, Inc. Compounds, compositions, and methods
US7301028B2 (en) 2002-06-14 2007-11-27 Merck & Co., Inc. Mitotic kinesin inhibitors
GB0214139D0 (en) * 2002-06-19 2002-07-31 Glaxo Group Ltd Chemical compounds
JP2005537257A (ja) 2002-07-08 2005-12-08 メルク エンド カムパニー インコーポレーテッド 有糸分裂キネシン結合部位
WO2004006865A2 (en) 2002-07-17 2004-01-22 Cytokinetics, Inc. Compounds, compositions, and methods
JP2006501201A (ja) 2002-07-23 2006-01-12 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
WO2004018058A2 (en) 2002-08-21 2004-03-04 Cytokinetics, Inc. Compounds, compositions, and methods
EP1554265A4 (en) 2002-09-13 2008-05-07 Cytokinetics Inc COMPOSITIONS, COMPOSITIONS AND M THODES
EP1620092A4 (en) 2003-05-07 2008-04-16 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
WO2004103282A2 (en) 2003-05-15 2004-12-02 Cytokinetics, Inc. Compounds, compositions and methods
ATE419249T1 (de) * 2004-04-06 2009-01-15 Novartis Vaccines & Diagnostic Inhibitoren von mitotischem kinesin
CA2564215A1 (en) * 2004-05-21 2005-12-01 Chiron Corporation Substituted quinoline derivatives as mitotic kinesin inhibitors
AU2005258135B2 (en) * 2004-06-18 2011-09-22 Novartis Vaccines And Diagnostics Inc. N- (1- (1-benzyl -4-phenyl-1H-imidazol-2-YL) -2,2-dymethylpropyl) benzamide derivatives and related compounds as kinesin spindle protein (KSP) inhibitors for the treatment of cancer
AU2005301133A1 (en) * 2004-10-19 2006-05-11 Novartis Vaccines And Diagnostics Inc. Indole and benzimidazole derivatives
US7829589B2 (en) * 2005-06-10 2010-11-09 Elixir Pharmaceuticals, Inc. Sulfonamide compounds and uses thereof
MY147188A (en) * 2005-08-09 2012-11-14 Novartis Ag Substituted imidazole compounds as ksp inhibitors
US8129358B2 (en) * 2006-11-13 2012-03-06 Novartis Ag Substituted pyrazole and triazole compounds as KSP inhibitors

Also Published As

Publication number Publication date
JP2010509365A (ja) 2010-03-25
ECSP099326A (es) 2009-06-30
EP2091926B1 (en) 2015-10-21
IL198471A0 (en) 2010-02-17
SMAP200900045A (it) 2009-07-14
US20080200462A1 (en) 2008-08-21
CN101558049A (zh) 2009-10-14
CL2007003272A1 (es) 2008-03-24
CO6382171A2 (es) 2012-02-15
GT200900122A (es) 2011-09-14
TN2009000178A1 (en) 2010-10-18
AR063805A1 (es) 2009-02-18
AU2007323998B2 (en) 2011-09-22
US8129358B2 (en) 2012-03-06
EP2091926A1 (en) 2009-08-26
MX2009005071A (es) 2009-05-25
ZA200902940B (en) 2010-05-26
CN101558049B (zh) 2012-08-15
WO2008063912A1 (en) 2008-05-29
AU2007323998A1 (en) 2008-05-29
MA30959B1 (fr) 2009-12-01
NI200900084A (es) 2010-01-29
ES2557478T3 (es) 2016-01-26
HN2009000968A (es) 2011-10-25
TW200831480A (en) 2008-08-01
UA97256C2 (ru) 2012-01-25
KR20090081020A (ko) 2009-07-27
EA017748B1 (ru) 2013-02-28
PE20081169A1 (es) 2008-09-24
EA200900631A1 (ru) 2009-12-30
NZ576640A (en) 2011-10-28
GEP20125389B (en) 2012-01-25
CA2668661A1 (en) 2008-05-29
DOP2009000106A (es) 2009-05-31
US7902240B2 (en) 2011-03-08
US20100034813A1 (en) 2010-02-11
SMP200900045B (it) 2010-03-01
JP5264755B2 (ja) 2013-08-14
CR10787A (es) 2009-07-02
BRPI0719002A2 (pt) 2013-12-17

Similar Documents

Publication Publication Date Title
NO20092226L (no) Substituerte pyrazol og triazolforbindelser som KSP-inhibitorer
MX2009007260A (es) Derivados de imidazol como inhibidores de proteina de huso de cinesina (eg-5).
MX2011013771A (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17.
MY147188A (en) Substituted imidazole compounds as ksp inhibitors
TW200612958A (en) Substituted imidazole derivatives
WO2009016460A8 (en) Pyrazole compounds and their use as raf inhibitors
MX2007004699A (es) Derivados de indol y bencimidazol.
TW200833675A (en) Nicotinamide derivatives
MX2009008506A (es) Derivados del pirazol como inhibidores de 11-b-hsd1.
NO20083717L (no) Pyrrolotriazin-anilin prodrugforbindelser anvendbare som kinaseinhibitorer
ECSP10010447A (es) Inhibidores de cinasa pim y métodos para su uso
NO20084418L (no) Azolopyridin-3-on derivater som inhibitorer av endoteliallipase
RS53638B1 (en) CRYSTAL SOLVATES OF DERIVATIVES (1S) -1,5-ANHYDRO-1-C- (3 - ((PHENYL) METHYL) PHENYL) -D-GLUCITOL WITH ALCOHOLS AS INHIBITORS OF SGLT2 FOR TREATMENT OF DIABETES
WO2007117465A3 (en) Indazole compounds
NO20071617L (no) Indozolonderivater som 11B-HSD1-inhibitorer
NO20083726L (no) Spiroindolinon derivater
CA2757418C (en) Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same
DK1753723T3 (da) Substituerede quinolinderivater som mitotiske kinesininhibitorer
MX2012003982A (es) Pirrolidinas n-substituidas.
MX2012004089A (es) Inhibidores de hsp90.
MX2009010302A (es) Derivados de indol que tienen actividad inhibidora de cpla2 y aplicaciones y metodos de produccion.
NO20084543L (no) Benzimidazolderivater
NO20080110L (no) Benzimidazolderivativer som 5-HT6,5-HT24
MX2009013003A (es) Derivados de piperidina-amida.
NO20082589L (no) Nye indolizinderivater, fremgangsmate for fremstilling av samme og terapeutiske sammensetninger som inbefatter samme

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application